Predict your next investment

Private Equity
FINANCE | Investment Banking
healthcareroyalty.com

See what CB Insights has to offer

Investments

20

Portfolio Exits

4

Funds

8

Partners & Customers

4

Service Providers

1

About HealthCare Royalty Partners

HealthCare Royalty Partners is a global healthcare investment firm launched in 2007. HC Royalty specializes in making structured investments in commercial-stage healthcare companies and products. HC Royalty invests in commercial stage healthcare companies and products across a broad range of therapeutic areas around the globe. The firm targets investments between $20 million and $100 million, but can execute significantly larger transactions.

HealthCare Royalty Partners Headquarters Location

300 Atlantic Street Suite 600

Bridgeport, Connecticut, 06601,

United States

203-388-9080

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

HealthCare Royalty Partners Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

HealthCare Royalty Partners Rank

Latest HealthCare Royalty Partners News

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 9, 2022

- Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “We are building significant momentum through our internal and partnered programs leveraging our proprietary SCS platform technology,” said George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer. “We have created a new paradigm in retinal drug delivery with XIPERE ® for suprachoroidal use. It is the first product approved by the U.S. FDA for suprachoroidal injection and is now being used by physicians across the U.S. to treat patients with macular edema associated with uveitis.” Dr. Lasezkay continued, “There are multiple upcoming anticipated catalysts related to our internal CLS-AX program and from our development and commercialization partners. We successfully completed dosing in Cohorts 3 and 4 of OASIS, our Phase 1/2a clinical trial of CLS-AX in patients with neovascular age-related macular degeneration (wet AMD). We expect to report the OASIS data for all four cohorts in November of this year, which we believe will provide more insight into the potential benefits of combining pan-VEGF inhibition from the highly potent tyrosine kinase inhibitor, axitinib, with targeted delivery to affected chorioretinal tissues utilizing our proprietary SCS Microinjector.” Key Highlights Completed dosing in Cohorts 3 and 4 of OASIS, Clearside’s U.S. based, open-label, dose-escalation Phase 1/2a clinical trial of CLS-AX in patients with wet AMD. Entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners, which may provide Clearside up to $65 million in non-dilutive funding to support ongoing clinical development of Clearside’s pipeline, and pursuant to which HealthCare Royalty Partners will receive all royalties and milestone payments due to Clearside from XIPERE and certain SCS Microinjector license agreements, subject to a cap of 2.5 times the total purchase price paid by HealthCare Royalty under the agreement; the cap may be increased under certain circumstances. Clearside’s commercialization partner, Bausch + Lomb, received XIPERE’s permanent J-code, a reimbursement code used in the US by commercial insurers and government payers, which became effective for provider billing on July 1, 2022. Appointed Susan L. Coultas, Ph.D., as Chief Clinical Officer. Clearside’s proprietary suprachoroidal space injection platform was highlighted in the July 2022 special edition of Retinal Physician and in multiple presentations and panels at global conferences, including the American Society of Retina Specialists (ASRS) Annual Meeting, the Ophthalmology Innovation Source (OIS) Retina Innovation Summit, and the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. A data manuscript entitled, “Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)” was published in the British Journal of Ophthalmology in June 2022. A data manuscript entitled, “Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema” was published in the American Journal of Ophthalmology in May 2022. A data manuscript entitled, “Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina” was published in the Journal of Ocular Pharmacology in April 2022. Second Quarter 2022 Financial Results Clearside’s license and other revenue for the second quarter of 2022 was $384,000, compared to $780,000 for the second quarter of 2021. Research and development expenses for the second quarter of 2022 were $5.4 million, compared to $4.1 million for the second quarter of 2021. The $1.3 million increase was primarily attributable to CLS-AX Phase 1/2a clinical trial costs. General and administrative expenses for the second quarter of 2022 were $2.8 million, compared to $2.8 million for the second quarter of 2021. Net loss for the second quarter of 2022 was $7.8 million, or $0.13 per share of common stock, compared to a net loss of $6.1 million, or $0.11 per share of common stock, for the second quarter of 2021. On August 8, 2022 (Closing Date), Clearside entered into a non-dilutive financing agreement with HealthCare Royalty Partners for up to $65 million. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million, less certain expenses, within 15 business days of the Closing Date. At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE. The terms of the agreement also provide for an additional milestone payment of $20 million to Clearside upon attainment of a second pre-specified 2024 sales milestone for XIPERE. As of June 30, 2022, Clearside’s cash and cash equivalents totaled $29.0 million. The initial royalty agreement payment of $32.5 million combined with the second quarter-end cash balance is expected to provide financial runway into 2024. Conference Call & Webcast Details Clearside’s management will host a webcast and conference call today at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations . The Company suggests participants log in 15 minutes in advance of the event. About XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, formerly known as CLS-TA, is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis. Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, has the exclusive license for the commercialization and development of XIPERE in the United States and Canada. Arctic Vision, a specialty ophthalmology company based in China, has the exclusive license for the commercialization and development of XIPERE, which they refer to as Arcatus™, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries. XIPERE was approved by the U.S. Food and Drug Administration in October 2021 and is commercially available in the U.S. About Clearside Biomedical Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com . Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of CLS-AX, including the expected timing of data from the OASIS clinical trial, the potential benefits of CLS-AX and product candidates using Clearside’s SCS Microinjector®, the anticipated use of proceeds from the agreement with HealthCare Royalty Partners, potential future payments under the agreement with HealthCare Royalty Partners and Clearside’s ability to fund its operations into 2024. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, uncertainties regarding the COVID-19 pandemic and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (SEC) on March 11, 2022, and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor and Media Contacts:

HealthCare Royalty Partners Investments

20 Investments

HealthCare Royalty Partners has made 20 investments. Their latest investment was in Suneva Medical as part of their Series D on June 6, 2016.

CBI Logo

HealthCare Royalty Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/9/2016

Series D

Suneva Medical

$25M

No

3

4/8/2016

Series D

TearScience

$19.23M

No

2

7/29/2015

Debt - II

Suneva Medical

$20.4M

No

3

2/13/2015

Series F

Subscribe to see more

$99M

Subscribe to see more

10

9/17/2014

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/9/2016

4/8/2016

7/29/2015

2/13/2015

9/17/2014

Round

Series D

Series D

Debt - II

Series F

Private Equity

Company

Suneva Medical

TearScience

Suneva Medical

Subscribe to see more

Subscribe to see more

Amount

$25M

$19.23M

$20.4M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

3

10

10

HealthCare Royalty Partners Portfolio Exits

4 Portfolio Exits

HealthCare Royalty Partners has 4 portfolio exits. Their latest portfolio exit was Suneva Medical on January 12, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/12/2022

Acq - Pending

$99M

1

9/6/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/15/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

4/19/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/12/2022

9/6/2017

6/15/2015

4/19/2011

Exit

Acq - Pending

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

HealthCare Royalty Partners Acquisitions

1 Acquisition

HealthCare Royalty Partners acquired 1 company. Their latest acquisition was Helomics on November 12, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/12/2014

Debt

$99M

$155.06M

Acq - Fin

1

Date

11/12/2014

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$155.06M

Note

Acq - Fin

Sources

1

HealthCare Royalty Partners Fund History

8 Fund Histories

HealthCare Royalty Partners has 8 funds, including HealthCare Royalty Partners IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/9/2020

HealthCare Royalty Partners IV

UNKNOWN

Closed

$1,830M

1

11/13/2019

HealthCare Royalty Partners IV-A

$99M

10

10/20/2014

Healthcare Royalty Partners III LP

Subscribe to see more

Subscribe to see more

$99M

10

1/5/2012

Cowen Healthcare Royalty Partners II LP

Subscribe to see more

Subscribe to see more

$99M

10

9/1/2009

Cowen Healthcare Royalty Partners Annex Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

1/9/2020

11/13/2019

10/20/2014

1/5/2012

9/1/2009

Fund

HealthCare Royalty Partners IV

HealthCare Royalty Partners IV-A

Healthcare Royalty Partners III LP

Cowen Healthcare Royalty Partners II LP

Cowen Healthcare Royalty Partners Annex Fund

Fund Type

UNKNOWN

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$1,830M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

HealthCare Royalty Partners Partners & Customers

4 Partners and customers

HealthCare Royalty Partners has 4 strategic partners and customers. HealthCare Royalty Partners recently partnered with Nektar Therapeutics on December 12, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

12/22/2020

Licensor

United States

Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million

SAN FRANCISCO , Dec. 22 , 2020 / PRNewswire / -- Nektar Therapeutics today announced that it agreed to sell to entities managed by Healthcare Royalty Management , LLC its royalties on future sales of ADYNOVATE , under Nektar Therapeutics 's agreement with Baxalta Incorporated , a Takeda company , and MOVANTIK , under Nektar Therapeutics 's agreement with AstraZeneca AB .

2

9/16/2019

Licensor

United States

Subscribe to see more

Subscribe to see more

10

1/8/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

Licensee

United States

Subscribe to see more

Subscribe to see more

10

Date

12/22/2020

9/16/2019

1/8/2018

Type

Licensor

Licensor

Partner

Licensee

Business Partner

Country

United States

United States

United States

United States

News Snippet

Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million

SAN FRANCISCO , Dec. 22 , 2020 / PRNewswire / -- Nektar Therapeutics today announced that it agreed to sell to entities managed by Healthcare Royalty Management , LLC its royalties on future sales of ADYNOVATE , under Nektar Therapeutics 's agreement with Baxalta Incorporated , a Takeda company , and MOVANTIK , under Nektar Therapeutics 's agreement with AstraZeneca AB .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

HealthCare Royalty Partners Service Providers

1 Service Provider

HealthCare Royalty Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

HealthCare Royalty Partners Team

5 Team Members

HealthCare Royalty Partners has 5 team members, including current Chief Executive Officer, Managing Partner, Clarke Futch.

Name

Work History

Title

Status

Gregory B. Brown

Founder

Current

Clarke Futch

Chief Executive Officer, Managing Partner

Current

Thomas K Conner

Chief Financial Officer

Current

Warren D Cooper

Chief Medical Officer

Current

Matthew Reber

Paul Capital, Oak Hill Capital Partners, J.H. Whitney, and Morgan Stanley

Managing Director

Former

Name

Gregory B. Brown

Clarke Futch

Thomas K Conner

Warren D Cooper

Matthew Reber

Work History

Paul Capital, Oak Hill Capital Partners, J.H. Whitney, and Morgan Stanley

Title

Founder

Chief Executive Officer, Managing Partner

Chief Financial Officer

Chief Medical Officer

Managing Director

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.